TABLE IV.

Association of MBL2 genotypes on progression-free survival in children: Age (≥2 vs <2 y)

MBL2 genotypes Compared	Age ≥2 y: RH (95% CI), P value	Age <2 y: RH (95% CI), P value
O/O vs A/O*	0.83 (0.25-2.70), .75	2.28 (1.09, 4.79) p=0.029
Adjusted†	3.73 (0.71-19.6), .12	2.21 (0.94-5.15), .067
Adjusted‡	0.91 (0.26-3.16), .88	2.07 (0.95-4.49), .066
Adjusted§	0.88 (0.26-2.95), .84	2.27 (1.05-4.88), .036
O/O vs A/A*	1.05 (0.58-1.90), .87	1.54 (1.07-2.22), .02
Adjusted†	1.00 (0.46-2.17), .99	1.38 (0.92-2.08), .12
Adjusted‡	1.02 (0.56-1.88), .94	1.53 (1.04-2.24), .03
Adjusted§	1.11 (0.60-2.03), .74	1.53 (1.04-2.25), .029
O/O vs A/O+A/A*	0.97 (0.30-3.07), .95	2.33 (1.14-4.76), .02
Adjusted†	1.55 (0.35-6.83), .56	2.14 (0.98-4.69), .058
Adjusted‡	0.87 (0.27-2.87), .82	2.19 (1.05-4.55), .036
Adjusted§	1.04 (0.32-3.35), .95	2.33 (1.12-4.83), .024

^*Unadjusted.

^†Adjusted for CD4⁺ lymphocyte count, HIV-1 RNA, treatments, race, and sex.

^‡Adjusted for CCR5-wt/Δ32, -59029-G/A, CX₃CR1-249-V/I, -280-T/M, and SDF-1-180-G/A.

^§Adjusted for MBL2-H/L, MBL2-P/Q, and MBL2-X/Y.